Ocular Therapeutix Announces Proposed Public Offering Of Common Stock
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced today that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. The offering consists of 3,200,000 shares being offered by the Company and 800,000 shares being offered by certain stockholders of the Company. In addition, the selling stockholders are expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 600,000 shares of the Company’s common stock at the public offering price, less the underwriting discount. Ocular Therapeutix will not receive any proceeds from the sale of shares by the selling stockholders. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
Morgan Stanley, Cowen and Company and RBC Capital Markets are acting as joint book-running managers for the offering. Nomura and BTIG are acting as co-managers for the offering. The offering is being made only by means of a prospectus. Copies of the preliminary prospectus relating to this offering may be obtained by contacting Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717; RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281; Nomura Securities International, Inc., Attention: ECM Syndicate Department, 309 West 49th Street, 5th Floor, New York, NY 10019; or BTIG, LLC, Attention: U.S. Syndicate, 825 3rd Avenue, 6th Floor, New York, NY 10022.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix’s lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and Phase 2 clinical development for glaucoma, allergic conjunctivitis and inflammatory dry eye disease. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix’s first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.
Ocular Therapeutix, Inc.
Chief Financial Officer
Burns McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich, 212-213-0006
Ocular Therapeutix, Inc.
Vice President of Sales and Marketing